AusperBio Raises $63 Million in Series B2 Financing to Accelerate Functional Cure Therapies for Chronic Hepatitis B
Summary
AusperBio Therapeutics closed a $63 million Series B2 financing round backed by its existing investors and new strategic support. The company will use the capital to advance AHB-137 through pivotal and Phase II studies and expand its global development program. It will also invest in its Med-Oligo ASO platform, preclinical pipeline, and commercial manufacturing partnerships. The financing strengthens AusperBio’s plans to pursue a functional cure for chronic hepatitis B and broaden its future pipeline.
Funding
Amount
$63.0M
Total raised
Date
September 21, 2025
Announcement date
Investors
CDH Investments, Qiming Venture Partners, Genesis Capital, Sherpa Capital
Lead investors
Company
http://www.ausperbio.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected